Navigation Links
Groundbreaking Study Published in Nature Biotechnology Demonstrates Sensitivity of Single Molecule Test for Detection of Prostate Cancer

CAMBRIDGE, Mass., May 23 /PRNewswire/ -- Quanterix Corporation, the single molecule diagnostics company focused on developing and commercializing high sensitivity tests, announced the publication of a breakthrough study of the company's proprietary technology that demonstrates an unprecedented sensitivity for measuring a biomarker for prostate cancer recurrence. The research article, featured on the cover of the June issue (Volume 28, No. 6) of Nature Biotechnology, describes how researchers developed a simple blood test using Quanterix's Single Molecule Array (SiMoA™) technology to selectively capture and measure individual Prostate Specific Antigen (PSA) molecules in prostate cancer patients.  The study showed that SiMoA was 1,700 times more sensitive than standard hospital tests, potentially allowing for detection of prostate cancer recurrence years earlier than current tests.

To demonstrate the clinical potential of SiMoA, PSA was measured in serum from men who had undergone radical prostatectomy for prostate cancer.  For the majority of these patients PSA is initially reported as undetectable following surgery, but may be present at very low levels that predict the likelihood of disease recurrence.  The Quanterix test was so sensitive that it was able to measure residual PSA levels in all samples tested.  The PSA levels had been reported to be undetectable in these samples by standard tests, highlighting the sensitivity and precision of the SiMoA technology.

"This paper demonstrates the extraordinary sensitivity provided by our SiMoA platform.  Its single molecule resolution has allowed us to measure PSA at extremely low levels, rather than having to wait until the cancer is more advanced," said Dr. David C. Duffy, Senior Director of Platform Research, Quanterix and corresponding author of the study.  "By using Quanterix's high density arrays, we were able to hone in on individual molecules rather than looking at the average response of thousands of molecules.  SiMoA provides the resolution for the proteome that the Hubble telescope did for the cosmos."

"A diagnostic test with this sensitivity may eliminate unnecessary secondary treatment while also providing significant peace of mind for the over 100,000 American men who annually undergo radical prostatectomy for the treatment of prostate cancer and who will ultimately remain disease-free," said Dr. Herbert Lepor, a prostate cancer expert and Chairman of the Department of Urology at the New York University School of Medicine.   "New York University Langonne Medical Center is looking forward to investigating the Quanterix test to determine its potential for identifying patients who require more or less vigilant follow-up after surgery and, identifying earlier those men who require secondary treatment, thereby optimizing postoperative management."

"The implications of this technology are far reaching," noted David Walt, Ph.D., scientific founder of both Quanterix and Illumina ( ILMN).  "In analytical chemistry, single molecule counting is the ultimate goal for sensitivity.  This report shows the applicability of SiMoA in measuring an important cancer marker and opens the door for its application in many other areas including neurological, cardiovascular and autoimmune diseases."  

"Quanterix has demonstrated conclusively that SiMoA can be applied to measuring any protein of interest with unprecedented sensitivity," said Dr. David Okrongly, President and CEO of Quanterix.  "Our goal is to utilize these data and other studies to launch our first diagnostic tests through the Quanterix Clinical Laboratory by 2011 and continue to advance the technology towards implementation across the full spectrum of immunodiagnostics."  

About Quanterix

Quanterix Corporation is a development stage diagnostics company utilizing proprietary Single Molecule Array (SiMoA™) technology for the quantification of clinically important proteins.  SiMoA is the most sensitive immunoassay technology available and will bring an unprecedented level of insight into disease detection, diagnosis and surveillance using simple blood-based tests. The company is initially focused on biomarkers for prostate cancer recurrence monitoring and central nervous system disorders, such as Alzheimer's disease. The company will commercialize its high value tests through the Quanterix Clinical Laboratory, serving both clinicians for patient testing and pharmaceutical companies to support clinical trials.  Founded in 2007, the privately held Cambridge, Massachusetts based company is backed by leading life science investors including ARCH Venture Partners, Bain Capital Ventures, and Flagship Ventures.  For additional information, please visit

SOURCE Quanterix Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
2. Sensitechs Groundbreaking TempTale(R)4 USB Dry Ice Temperature Monitor Provides Fast, Simple, Efficient Cold Chain Visibility
3. Groundbreaking Ceremony in Port-au-Prince, Haiti for FilterPure Water Filtration Factory
4. Shanghai ChemPartner Is Pleased to be Part of Agios Groundbreaking Cancer Research
5. UNT Health Science Centers Groundbreaking Research Applied to Protecting Brain After Traumatic Injury
6. Stand Up To Cancer Awards $73.6 Million for Novel, Groundbreaking Cancer Research
7. Lake Hospital System Receives $60,000 Grant for Groundbreaking Music Therapy Study
8. Groundbreaking Paper Publishes Long Term Results of a Successful Phase I Clinical Trial Using Autologous Neural Stem Cells to Treat Parkinsons Disease
9. Groundbreaking American Journal of Play from Strong National Museum of Play(R) Premiers July 2008
10. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
11. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
Post Your Comments:
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Brain Monitoring Devices Market 2015-2019" ... Research and Markets ( ) ...
(Date:11/25/2015)...  Linden Care, LLC, a retail specialty pharmacy focused ... suffering from chronic pain, said today that it is ... (TRO) enjoining Express Scripts from unilaterally terminating the Pharmacy ... --> --> The company said that ... --> --> In ...
(Date:11/25/2015)... Nov. 25, 2015  Henry Schein, Inc., the world,s ... office-based dental, medical and animal health practitioners, will unveil ... Henry Schein ConnectDental® Pavilion , which brings together ... open solutions designed to help any practice or laboratory ... for a schedule of experts appearing at the ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the ... several models of traditional and far-infrared saunas. , For traditional saunas, Finnleo ... most traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White ...
(Date:11/25/2015)... ... 2015 , ... On November 10, 2015, Bohrer Brady, LLC filed a class ... of a home health care worker who provided companionship services for the elderly, ill ... employed by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), Inc. ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 25, 2015, officials of ... network, announced the release of a new cutting edge recovery program that has been ... working with drug- and alcohol-addicted individuals with the purpose to free addicts from the ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... certified facial plastic surgeon specializing in both surgical and non-surgical treatments, announced the ... Spa at Hobgood Facial Plastic Surgery. , Highly trained and nationally recognized ...
(Date:11/25/2015)... ... ... Today, Mothers Against Drunk Driving (MADD) learned that the number of ... time since 2011. In 2014, there were 9,967 fatalities involving an alcohol impaired driver, ... Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in 2014. Drunk ...
Breaking Medicine News(10 mins):